ライフサイエンスコーパス: MIBG

1 MIBG imaging was significantly more sensitive than FDG-P

2 MIBG scan is significantly more sensitive for individual

3 to patient/body region was 80%/65% for 123I-MIBG and 88%/70% for [18F]FDA-PET.

4 s pretreatment (80%/65%) sensitivity of 123I-MIBG scintigraphy.

5 False-negative results on 123I-MIBG scintigraphy and/or [18F]FDA-PET were not predicted

6 of regions that were false negative on 123I-MIBG scintigraphy or [18F]FDA-PET were detected by [18F]

7 ter iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patients with resistant neuroblastoma

8 n = 148) were treated with 18 mCi/kg of 131I-MIBG.

9 imilar before and after chemotherapy or 131I-MIBG treatment, except for a trend toward lower post- (6

10 mal GFR (> or = 100 mL/min/1.73 m2) was 131I-MIBG 12 mCi/kg, carboplatin 1,500 mg/m2, etoposide 1,200

11 te and low nonhematologic toxicity with 131I-MIBG suggest incorporation of this agent into initial mu

12 -metaiodobenzylguanidine ((124)I-MIBG) in an MIBG-avid model was performed.

13 e, 22% higher than that of (124)I-MIBG in an MIBG-avid neuroblastoma model.

14 adionuclide studies consisting of PET-CT and MIBG scintigraphy.

15 up and further characterized with PET-CT and MIBG scintigraphy.

16 d pressure monitoring, echocardiography, and MIBG imaging.

17 esions identified on concomitant FDG-PET and MIBG scans and gave scans a semiquantitative score.

18 rdiac sympathetic denervation as assessed by MIBG imaging is a useful prognostic marker in transthyre

19 or patients with neuroblastoma detectable by MIBG or marrow analysis.

20 ocardial sympathetic denervation detected by MIBG imaging in transthyretin familial amyloid polyneuro

21 Patients with disease evaluable only by MIBG and/or BM histology had a 21.7% CR rate to hu14.8-I

22 t always correlate with complete response by MIBG uptake.

23 han (11)C-HED and 12 times slower than (11)C-MIBG.

24 ry, characterized by initial loss of cardiac MIBG signal and 11C-colonic donepezil signal followed by

25 take followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal.

26 Nonradioactive carrier MIBG molecules inhibit uptake of (131)I-MIBG, theoretica

27 ncordance of positive lesions on concomitant MIBG and FDG-PET scans was 39.6% when examining the 139

28 The estimated MIBG distribution volumes (V(d)) for transduced Jurkat,

29 ucose-positron emission tomography scans for MIBG-nonavid disease, replace technetium-99m diphosphona

30 ients injected with (68)Ga-DOTATOC or (123)I MIBG emitted an average EDR-1m roughly half that of pati

31 (123) I-FP-CIT SPECT and (123) I-MIBG myocardial scintigraphy have similar sensitivity fo

32 cts of diabetes and heart disease on (123) I-MIBG myocardial scintigraphy results might have been ove

33 s underwent (123) I-FP-CIT SPECT and (123) I-MIBG myocardial scintigraphy within a few weeks of clini

34 B were respectively 93% and 100% for (123) I-MIBG myocardial scintigraphy, and 90% and 76% for (123)

35 omitant parkinsonism) who had normal (123) I-MIBG myocardial uptake.

36 pposed to potentially interfere with (123) I-MIBG uptake.

37 y (P < 0.05) for (201)Tl (2.04-fold), (123)I-MIBG (3.25-fold), and (3)H-l-methionine (3.11-fold).

38 g (99m)Tc-tetrofosmin (26 +/- 6 MBq), (123)I-MIBG (54 +/- 14 MBq), and a CZT camera.

39 exposure, (18)F-FDG (one occasion) or (123)I-MIBG (other occasion) was administered.

40 ish the optimal time interval between (123)I-MIBG administration and subsequent SPECT/CT acquisition

41 SPECT/CT scans acquired at 4 h after (123)I-MIBG administration and the SPECT/CT scans acquired at 2

42 SPECT/CT was performed at 24 h after (123)I-MIBG administration, the magnitude of BAT activity measu

43 SPECT/CT scans acquired at 24 h after (123)I-MIBG administration.

44 he curie scores were recorded for the (123)I-MIBG and (124)I-MIBG scans.

45 In 8 pairs, (123)I-MIBG and (124)I-MIBG were performed within 1 mo of each

46 A total of 113 paired (123)I-MIBG and (18)F-FDG PET scans in 60 patients with neurobl

47 (123)I-MIBG and (18)F-FDG showed equal numbers of lesions in 1

48 (123)I-MIBG and (18)F-FDG were equal in 2 of 15 scans, and 4 of

49 (123)I-MIBG and (18)F-FDG were equivalent or complementary in 1

50 ts with tumors that weakly accumulate (123)I-MIBG and at major decision points during therapy (i.e.,

51 )F-FDG and semiquantitative uptake of (123)I-MIBG at 24 h after administration (r = 0.64, P = 0.04).

52 )F-FDG and semiquantitative uptake of (123)I-MIBG at 4 h after administration.

53 (123)I-MIBG cardiac washout was lower during carvedilol than me

54 In contrast, (18)F-LMI1195 and (123)I-MIBG demonstrated stable storage at the nerve terminal w

55 euroblastoma (15 scans, 10 patients), (123)I-MIBG depicted more extensive primary neuroblastoma or lo

56 euroblastoma (85 scans, 40 patients), (123)I-MIBG depicted more neuroblastoma sites in 44 of 85 scans

57 was only approximately twice that of (123)I-MIBG despite the large difference in half-lives (100 vs.

58 sulted as an independent predictor of (123)I-MIBG early and late heart:mediastinum ratio and single-p

59 EAT thickness correlated with (123)I-MIBG early and late heart:mediastinum ratio and single-p

60 s on cardiac sympathetic denervation ((123)I-MIBG early and late heart:mediastinum ratio and single-p

61 I-MIBG small-animal PET compared with (123)I-MIBG gamma-camera/SPECT.

62 Although (123)I-MIBG has been in clinical use for the imaging of pheochr

63 raphic and clinical variables and the (123)I-MIBG heart-to-mediastinum ratio (H/M).

64 Before (131)I-MIBG therapy, standard (123)I-MIBG imaging (5.2 MBq/kg) was performed on 7 patients, i

65 the independent predictive ability of (123)I-MIBG imaging for mortality outcomes.

66 (123)I-MIBG imaging has several limitations that can be overcom

67 (123)I-MIBG imaging is a mainstay in the evaluation of neurobla

68 2%-88% and specificity of 82%-84% for (123)I-MIBG imaging used in the diagnostic assessment of primar

69 on of (18)F-LMI1195 was compared with (123)I-MIBG in MENX mut/mut rats (n = 6) and correlated with hi

70 -LMI1195, (11)C-hydroxyephedrine, and (123)I-MIBG in rabbit hearts.

71 To clarify the normal kinetics of (123)I-MIBG in vivo over time, we designed an experimental prot

72 nderwent planar acquisition 4 h after (123)I-MIBG injection (191 +/- 41 [mean +/- SD] MBq).

73 G SPECT/CT, when performed 24 h after (123)I-MIBG injection, as a method to visualize and quantify sy

74 /CT was performed at 4 and 24 h after (123)I-MIBG injection.

75 (123)I-MIBG is overall superior in the evaluation of stage 4 ne

76 stage 1 and 2 neuroblastoma, although (123)I-MIBG may be needed to exclude higher-stage disease.

77 s sympathetic activity as measured by (123)I-MIBG myocardial washout.

78 se Criteria or (for MP) by changes in (123)I-MIBG or PET scans.

79 nificant additive predictive value on (123)I-MIBG planar and single-photon emission computed tomograp

80 tection for (124)I-MIBG PET/CT versus (123)I-MIBG planar imaging (P < 0.0001) and (123)I-MIBG SPECT/C

81 igher for (124)I-MIBG PET/CT than for (123)I-MIBG planar imaging and SPECT/CT in 6 of 10 patients.

82 ection capability superior to that of (123)I-MIBG planar imaging and SPECT/CT.

83 (124)I-MIBG PET/CT as well as paired (123)I-MIBG planar imaging and SPECT/CT.

84 disease present; 49, disease absent), (123)I-MIBG planar scintigraphy had a sensitivity and specifici

85 (123)I-MIBG scan is essential for valid estimation of the durat

86 (123)I-MIBG scan was the most reliable study for revealing unsu

87 Among asymptomatic patients, (123)I-MIBG scan was the sole positive study indicating relapse

88 Patients whose monitoring included (123)I-MIBG scan were significantly less likely than patients m

89 Without monitoring that includes (123)I-MIBG scan, caution should be used when comparing RFS bet

90 We applied scoring systems to (123)I-MIBG scanning and (18)F-DOPA PET/CT (i.e.,(123)I-MIBG WB

91 efractory VT underwent 15-min and 4-h (123)I-MIBG scans before and 6 mo after the ablation procedure.

92 A retrospective analysis of (123)I-MIBG scans obtained from patients who had been prospecti

93 (123)I-MIBG scans were evaluated at 2 time points, diagnosis (n

94 Among the 18 tumors with concomitant (123)I-MIBG scans, 4 tumors with viable cells were (123)I-MIBG-

95 (123)I-MIBG scans, or [(18)F]fluorodeoxyglucose-positron emissi

96 ance as directly compared with paired (123)I-MIBG scans.

97 If (18)F-DA PET is not available, (123)I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) an

98 emonstrated a higher sensitivity than (123)I-MIBG scintigraphy (n = 18; P = 0.0455) or (18)F-FDG PET

99 atients and might be complementary to (123)I-MIBG scintigraphy and (18)F-FDG PET.

100 ve confirmation of the performance of (123)I-MIBG scintigraphy for the evaluation of patients with kn

101 EO, because it is more sensitive than (123)I-MIBG scintigraphy or SRS.

102 was 90.2% for (18)F-DA PET, 76.0% for (123)I-MIBG scintigraphy, and 22.0% for SRS.

103 was 75.4% for (18)F-DA PET, 63.4% for (123)I-MIBG scintigraphy, and 64.0% for SRS.

104 ar medicine modalities: (18)F-DA PET, (123)I-MIBG scintigraphy, or SRS.

105 (123)I-MIBG SPECT has been shown to be complementary to planar

106 Moreover, (123)I-MIBG SPECT has been used in numerous studies to document

107 This review examines recent trends in (123)I-MIBG SPECT imaging and evidence that provides the basis

108 s superior quantitative capabilities, (123)I-MIBG SPECT is, for the foreseeable future, the only wide

109 erity of innervation abnormalities in (123)I-MIBG SPECT, programs and protocols specifically for (123

110 -MIBG planar imaging (P < 0.0001) and (123)I-MIBG SPECT/CT (P < 0.0001).

111 We aimed to determine whether (123)I-MIBG SPECT/CT and (18)F-FDG PET/CT identify the same ana

112 de SPECT/CT studies and 186 MBq in 10 (123)I-MIBG SPECT/CT studies.

113 Moreover, when (123)I-MIBG SPECT/CT was performed at 24 h after (123)I-MIBG ad

114 (123)I-MIBG SPECT/CT, as a marker of sympathetic activity, and

115 ically influenced but also identifies (123)I-MIBG SPECT/CT, when performed 24 h after (123)I-MIBG inj

116 diagnostic procedures such as MRI or (123)I-MIBG SPECT/CT.

117 Most cardiac (123)I-MIBG studies have relied on measurements from anterior p

118 3D dynamic analysis of (123)I-MIBG suggests that myocardial peak uptake is reached mor

119 (123)I-MIBG targets cell membrane and vesicular catecholamine t

120 mine chase did not change the cardiac (123)I-MIBG uptake (delayed heart-to-mediastinum ratio, 1.99 +/

121 take of (18)F-LMI1195 correlated with (123)I-MIBG uptake (r = 0.91), histological tumor volume (r = 0

122 glands by evaluating semiquantitative (123)I-MIBG uptake and to examine genotype-specific differences

123 All subjects who showed (123)I-MIBG uptake in BAT also showed (18)F-FDG uptake in BAT.

124 Liver-normalized semiquantitative (123)I-MIBG uptake may be helpful to distinguish between pheoch

125 (123)I-MIBG uptake significantly correlated with maximum tumor

126 ermination of the late HMR of cardiac (123)I-MIBG uptake using dual-isotope ((123)I and (99m)Tc) acqu

127 observed in 8 of 10 subjects, whereas (123)I-MIBG uptake was observed in 7 of 10 subjects in both the

128 tistically significant differences in (123)I-MIBG uptake were found across PPGLs of different genotyp

129 (123)I-MIBG uptake, however, did not correlate with either NET

130 do not translate into differences in (123)I-MIBG uptake.

131 The myocardial MSI of (123)I-MIBG was reached within 5.57 +/- 4.23 min (range, 2-12 m

132 )F-DOPA PET/CT is more sensitive than (123)I-MIBG WBS in staging neuroblastoma patients and evaluatin

133 scanning and (18)F-DOPA PET/CT (i.e.,(123)I-MIBG WBS score and whole-body metabolic burden [WBMB], r

134 72%, 33%, and 38%, respectively, for (123)I-MIBG WBS versus 83%, 75% and 54%, respectively, for (18)

135 83%, 50%, and 92%, respectively, for (123)I-MIBG WBS versus 94%, 92%, and 100%, respectively, for (1

136 ely-significantly higher than that of (123)I-MIBG WBS, at 28% and 69%, respectively.

137 ely-significantly higher than that of (123)I-MIBG WBS, at 41% and 93%, respectively.

138 contemporaneous images obtained using (123)I-MIBG were also reviewed for the presence of BAT.

139 Results: (123)I-MIBG whole-body planar scans, focused-field-of-view SPEC

140 T results were compared with those of (123)I-MIBG whole-body scanning (WBS).

141 ch as (123)I-metaiodobenzylguanidine ((123)I-MIBG) and (11)C-(-)-meta-hydroxyephedrine ((11)C-HED) ar

142 with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with

143 cs of (123)I-metaiodobenzylguanidine ((123)I-MIBG) are scarce and have always been obtained using pla

144 ce of (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging in heart failure subjects (median follow-u

145 (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging is a tool for evaluating one of the fundam

146 (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging is currently a mainstay in the evaluation

147 y by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either beta-blocker is used.

148 ed by (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging.

149 r iodine-123-metaiodobenzylguanidine ((123)I-MIBG) scan, urine catecholamines, and bone marrow (BM) h

150 ty of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (18)F-FDG PET in neuroblastoma.

151 se of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (18)F-FDG PET, using tumor histol

152 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy plays an important role in the diagno

153 ative (123)I-metaiodobenzylguanidine ((123)I-MIBG) scoring method (the Curie score, or CS) was previo

154 R) of (123)I-metaiodobenzylguanidine ((123)I-MIBG) uptake obtained using a multipinhole cadmium-zinc-

155 e and (123)I-metaiodobenzylguanidine ((123)I-MIBG) was examined by PET and planar scintigraphy, respe

156 ed by (123)I-metaiodobenzylguanidine ((123)I-MIBG).

157 nalog (123)I-metaiodobenzylguanidine ((123)I-MIBG).

158 Unlike (123)I-MIBG, (124)I-MIBG allows high-resolution PET.

159 3.39 for (201)TlCl, 9.77 +/- 6.06 for (123)I-MIBG, 37.30 +/- 14.42 for (99m)Tc-MIBI, 5.47 +/- 4.44 fo

160 BAT uptake of (18)F- or (3)H-FDG, (123)I-MIBG, and (3)H-l-methionine was significantly increased

161 eased uptake with (18)F- or (3)H-FDG, (123)I-MIBG, and (3)H-l-methionine, and the immunohistostaining

162 taneously with the bolus injection of (123)I-MIBG, and data were collected every 5 min for the first

163 All patients exhibited (123)I-MIBG-avid, International Neuroblastoma Staging System st

164 cans, 4 tumors with viable cells were (123)I-MIBG-negative but were successfully detected by (18)F-FD

165 all 8 patients who showed at least 1 (123)I-MIBG-positive lesion with a total of 10 scans.

166 nderwent one (18)F-FDG PET/CT and two (123)I-MIBG-SPECT/CT scans within a 2-wk interval.

167 h after (18)F-FDG administration, and (123)I-MIBG-SPECT/CT was performed at 4 and 24 h after (123)I-M

168 at can be noninvasively assessed with (123)I-MIBG.

169 PECT 24 h after the administration of (123)I-MIBG.

170 tudied with (18)F-FDG, (18)F-F-DA, or (123)I-MIBG.

171 c innervations in a manner similar to (123)I-MIBG.

172 BG was approximately 10 times that of (123)I-MIBG; however, given that we administered a very low act

173 e administered a very low activity of (124)I-MIBG (1.05 MBq/kg), the effective dose was only approxim

174 Unlike (123)I-MIBG, (124)I-MIBG allows high-resolution PET.

175 , on average, 22% higher than that of (124)I-MIBG in an MIBG-avid neuroblastoma model.

176 at later imaging times; at 73 h after (124)I-MIBG injection, the C6/hNET-IRES-GFP xenograft-to-muscle

177 : The first-in-humans use of low-dose (124)I-MIBG PET for monitoring disease burden demonstrated tumo

178 f-view SPECT/CT scans, and whole-body (124)I-MIBG PET scans found 25, 32, and 87 total lesions, respe

179 ield-of-view SPECT/CT, and whole-body (124)I-MIBG PET/CT (1.05 MBq/kg).

180 erapy, 2 of 7 patients also completed (124)I-MIBG PET/CT as well as paired (123)I-MIBG planar imaging

181 (124)I-MIBG PET/CT demonstrated better detection of lesions thr

182 We evaluated (124)I-MIBG PET/CT for its diagnostic performance as directly c

183 One patient underwent (124)I-MIBG PET/CT only after therapy.

184 The curie scores were also higher for (124)I-MIBG PET/CT than for (123)I-MIBG planar imaging and SPEC

185 nt difference in lesion detection for (124)I-MIBG PET/CT versus (123)I-MIBG planar imaging (P < 0.000

186 were recorded for the (123)I-MIBG and (124)I-MIBG scans.

187 ts demonstrated several advantages of (124)I-MIBG small-animal PET compared with (123)I-MIBG gamma-ca

188 e dose estimated for patient-specific (124)I-MIBG was approximately 10 times that of (123)I-MIBG; how

189 In 8 pairs, (123)I-MIBG and (124)I-MIBG were performed within 1 mo of each other.

190 with (124)I-metaiodobenzylguanidine ((124)I-MIBG) in an MIBG-avid model was performed.

191 PET/CT scans after administration of (124)I-MIBG, we estimated the effective dose of (124)I-MIBG.

192 G, we estimated the effective dose of (124)I-MIBG.

193 ed to (131)I-KX1, whereas cytoplasmic (125)I-MIBG demonstrated low biological effectiveness.

194 The planned treatment was (131)I-MIBG (444 or 666 MBq/kg) intravenously on day 1 plus ars

195 The treatment dose of NCA (131)I-MIBG (specific activity, 165 MBq/mug) was adjusted as ne

196 en compared with historical data with (131)I-MIBG alone.

197 published dosimetric organ values for (131)I-MIBG and (90)Y-DOTATOC along with critical organ-dose li

198 Fourteen patients received (131)I-MIBG and arsenic trioxide, both at maximal dosages; 2 pa

199 Combinations of PJ34 and (131)I-MIBG and of PJ34 and (131)I-MIBG/topotecan were also ass

200 Dose-intensified treatment with (131)I-MIBG at a fixed dose of 11.1 GBq (300 mCi) per cycle is

201 The addition of arsenic trioxide to (131)I-MIBG did not significantly improve response rates when c

202 Cumulative (131)I-MIBG given to achieve the target RMI ranged from 22 to 5

203 the evaluation of neuroblastoma, and (131)I-MIBG has been used for the treatment of relapsed high-ri

204 (131)I-MIBG has essentially been only palliative in paraganglio

205 termine the maximum-tolerated dose of (131)I-MIBG in two consecutive infusions at a 2-week interval,

206 ion of topotecan and PJ34 or PJ34 and (131)I-MIBG induced supraadditive toxicity in both cell lines.

207 1 therapeutic dose (~18.5 GBq) of HSA (131)I-MIBG intravenously.

208 Conclusion: HSA (131)I-MIBG offers multiple benefits, including sustained blood

209 treatment with 11.1 GBq (300 mCi) of (131)I-MIBG per cycle.

210 atients received a 666 MBq/kg dose of (131)I-MIBG plus a 0.15 mg/kg dose of arsenic trioxide.

211 atients received a 444 MBq/kg dose of (131)I-MIBG plus a 0.15 mg/kg dose of arsenic trioxide; and 3 p

212 (131)I-MIBG plus arsenic trioxide was well tolerated, with an a

213 Administration of HSV1716/NAT and (131)I-MIBG resulted in decreased tumor growth and enhanced sur

214 which was superior to the rates with (131)I-MIBG scan (64%; P = .1), bone scan (36%; P < .001), and

215 ed with one (4.5%) of 22 patients for (131)I-MIBG scan (P = .04) and 0% to 6% of patients for each of

216 ess likely than patients monitored by (131)I-MIBG scan to have an extensive osteomedullary relapse an

217 It is superior to (131)I-MIBG scintigraphy and conventional imaging (CT/MR imagin

218 A combination of CT/MR imaging and (131)I-MIBG scintigraphy detected only 53 of 78 (67.9%) lesions

219 (131)I-MIBG scintigraphy showed only 30 of the 78 lesions and w

220 tive improvements in semiquantitative (131)I-MIBG scores were observed in 6 patients.

221 (123)I/(131)I-MIBG theranostics have been applied in the clinical eval

222 erse event profile similar to that of (131)I-MIBG therapy alone.

223 (131)I-MIBG therapy was administered on days 0 and 14.

224 Methods: Before (131)I-MIBG therapy, standard (123)I-MIBG imaging (5.2 MBq/kg)

225 Mean absorbed dose of (131)I-MIBG to blood was 0.134 cGy/MBq, well below myeloablativ

226 am treatment enhanced the toxicity of (131)I-MIBG to spheroids and xenografts expressing the noradren

227 0 y old with resistant neuroblastoma, (131)I-MIBG uptake, and cryopreserved hematopoietic stem cells.

228 The NCA (131)I-MIBG was escalated from 444 to 777 MBq/kg (12-21 mCi/kg)

229 A diagnostic dose of NCA (131)I-MIBG was followed by 3 dosimetry scans to assess radiati

230 NCA (131)I-MIBG with autologous peripheral blood stem cell transpla

231 We previously reported that combining (131)I-MIBG with the topoisomerase I inhibitor topotecan induce

232 agent (131)I-metaiodobenzylguanidine ((131)I-MIBG) and tested the combination in a phase II clinical

233 using (131)I-metaiodobenzylguanidine ((131)I-MIBG) has produced remissions in some neuroblastoma pati

234 (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with advanced PPGL.

235 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) provides targeted radiotherapy with more than 30%

236 body (131)I-metaiodobenzylgunanidine ((131)I-MIBG) scintigraphy and conventional imaging (CT/MR imagi

237 temic (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy of neuroendocrine tumors comprises differe

238 n and (131)I-metaiodobenzylguanidine ((131)I-MIBG), a radiopharmaceutical used for the therapy of neu

239 ed at least 1 therapeutic dose of HSA (131)I-MIBG, 17 (25%; 95% confidence interval, 16%-37%) had a d

240 geted radiotherapy using radiolabeled (131)I-MIBG, a strategy that has already shown promise for comb

241 The antitumor efficacy of topotecan, (131)I-MIBG, and (131)I-MIBG/topotecan combination treatment wa

242 ceutical for high-risk neuroblastoma, (131)I-MIBG, is ineffective at targeting micrometastases due to

243 rier MIBG molecules inhibit uptake of (131)I-MIBG, theoretically resulting in less tumor radiation an

244 owed dramatic dose intensification of (131)I-MIBG, with minimal toxicity and promising activity.

245 erated dose of no-carrier-added (NCA) (131)I-MIBG, with secondary aims of assessing tumor and organ d

246 nd 11 with other tumors) treated with (131)I-MIBG.

247 d radionuclide therapy in the form of (131)I-MIBG.

248 ced the capacity for active uptake of (131)I-MIBG.

249 ng or after the administration of HSA (131)I-MIBG.

250 ived a treatment-planning dose of HSA (131)I-MIBG.

251 The PJ34 and (131)I-MIBG/topotecan combination treatment induced G(2) arrest

252 ficacy of topotecan, (131)I-MIBG, and (131)I-MIBG/topotecan combination treatment was increased by PA

253 vitro and in vivo, to further enhance (131)I-MIBG/topotecan efficacy.

254 ll scheduled combinations of PJ34 and (131)I-MIBG/topotecan induced supraadditive toxicity and increa

255 multaneous administration of PJ34 and (131)I-MIBG/topotecan significantly delayed the growth of SK-N-

256 and UVW/NAT xenografts, compared with (131)I-MIBG/topotecan therapy.

257 PJ34 and (131)I-MIBG and of PJ34 and (131)I-MIBG/topotecan were also assessed using similar scheduli

258 y, iodine-131-metaiodobenzylguanidine (131)I-MIBG; through November 1999) or iodine-123-metaiodobenzy

259 ography (PET) after i.v. infusion of [(123)I]MIBG or [(124)I]MIBG, respectively.

260 Response was evaluated by [(123)I]MIBG scans, computed tomography/magnetic resonance imagi

261 tro and also selectively accumulated [(123)I]MIBG.

262 ter i.v. infusion of [(123)I]MIBG or [(124)I]MIBG, respectively.

263 Cumulative [(131)I]MIBG administered ranged from 492 to 3,191 mCi.

264 ge 10 to 64 years, were treated with [(131)I]MIBG doses ranging from 492 to 1,160 mCi (median, 12 mCi

265 cryopreserved before treatment with [(131)I]MIBG greater than 12 mCi/kg or with a total dose greater

266 Sixty-nine [(131)I]MIBG infusions were given, which included infusions to 3

267 sponse rates achieved with high-dose [(131)I]MIBG suggest its utility in the management of selected p

268 Differences in MIBG accumulation between cell lines were primarily due

269 ET) substrates [123I]-m-iodobenzylguanidine (MIBG) and [11C]-m-hydroxyephedrine (HED) are used as mar

270 on emission tomography scans if the tumor is MIBG nonavid.

271 PDRBD+ and iRBD patients showed reduced mean MIBG heart:mediastinum ratios (P < 10-5, ANOVA) and colo

272 was compared with late heart-to-mediastinum MIBG uptake ratio (H/M; either in relation to the estima

273 ) innervation, 123I-metaiodobenzylguanidine (MIBG) scintigraphy to measure cardiac sympathetic innerv

274 iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreotide, and Tc-99m-methylene diphosp

275 enzyl)guanidine), a metaiodobenzylguanidine (MIBG) analog, for the detection of pheochromocytoma in a

276 oradrenaline analog metaiodobenzylguanidine (MIBG).

277 odine-123 ((123)I) -metaiodobenzylguanidine (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emissi

278 (123)I-metaiodobenzylguanidine (MIBG) and (111)In-pentetrotide SPECT have been used for

279 and cardiac (123)I-metaiodobenzylguanidine (MIBG) imaging.

280 (131)I-metaiodobenzylguanidine (MIBG) is specifically taken up in neuroblastoma, with a

281 A PET/CT and (123)I-metaiodobenzylguanidine (MIBG) scanning plus SPECT/CT.

282 ride (TlCl), (123)I-metaiodobenzylguanidine (MIBG), (99m)Tc-sestamibi (MIBI), (18)F- or (3)H-FDG, (3)

283 s (18)F-FDG, (123)I-metaiodobenzylguanidine (MIBG), and (99m)Tc-tetrofosmin have demonstrated uptake

284 ble only by [(123)I]metaiodobenzylguanidine (MIBG) scintigraphy and/or bone marrow (BM) histology (st

285 essed by 123-iodine metaiodobenzylguanidine (MIBG) imaging occurs early in disease progression.

286 ts targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of norepinephrine.

287 - or (124)I-labeled metaiodobenzylguanidine (MIBG) to high levels compared with the wild-type parent

288 for neuroblastoma: metaiodobenzylguanidine (MIBG) scan for uptake by the norepinephrine transporter

289 radiolabeled probe, metaiodobenzylguanidine (MIBG).

290 The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesi

291 radiotracers (e.g., metaiodobenzylguanidine [MIBG]).

292 zylguanidine ((18)F-MFBG) is a PET analog of MIBG that may allow for single-day, high-resolution quan

293 t-free survival and survival from the day of MIBG infusion for all patients at 3 years was 0.31 +/- 0

294 nd slow clearance (half-time, 63 +/- 6 h) of MIBG from transduced xenografts compared with that from

295 an doses were 0.92, 0.82, and 1.2 mGy/MBq of MIBG for the liver, lung, and kidney, respectively.

296 The use of two reporter probes (MIBG and 2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl-5-io

297 Responses by semiquantitative MIBG score occurred in eight patients, soft tissue respo

298 s became completely negative more often than MIBG scans after treatment.

299 eceptors and sympathetic integrity (from the MIBG scintigraphy) and the 30-to-15 ratio (a CART), rema

300 paragangliomas because of its homology with MIBG and the general advantages of PET imaging.